Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPhase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
British Journal of Cancer, 09/16/09
Munster PN et al. – Vorinostat can be combined with weekly doxorubicin in this schedule at a dose of 800 mg day^–1. The HDAC2 expression may be a marker predictive of HDAC inhibition. Antitumor activity of this regimen in breast cancer, prostate cancer, and melanoma seems interesting.
Related Articles
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Cancer Science, 10/26/09
Relevance Score: 89%
A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
Clinical Cancer Research, 11/06/09
Relevance Score: 85%
Molecular Targets in Malignant Pleural Mesothelioma Treatment
Current Drug Targets, 11/10/09
Relevance Score: 80%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, 12/04/09
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Three-dimensional (3D) Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to MEK Inhibitors
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Sponsor
Article Search
Sponsor